SELLAS Life Sciences Group, Inc. (SLS)
| Market Cap | 2.05B +873.8% |
| Revenue (ttm) | n/a |
| Net Income | -32.46M |
| EPS | -0.21 |
| Shares Out | 201.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,357,645 |
| Open | 10.42 |
| Previous Close | 10.38 |
| Day's Range | 9.85 - 11.09 |
| 52-Week Range | 1.39 - 15.88 |
| Beta | 2.57 |
| Analysts | Buy |
| Price Target | 32.50 (+220.04%) |
| Est. Earnings | Nov 11, 2026 |
About SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price target is $32.5, which is an increase of 220.04% from the latest price.
News
Sellas Life Sciences falls -17.7%
Sellas Life Sciences (SLS) is down -17.7%, or -$2.15 to $10.02.
SELLAS Life Sciences Stock (SLS) Slides 18% as a Phase 3 Study Enters Its Evaluation Period
SELLAS Life Sciences stock dropped over 18% on Wednesday alongside a clinical trial update.
Sellas Life Sciences triggers final analysis of REGAL trial
Sellas Life Sciences (SLS) announced that the pivotal Phase 3 REGAL trial evaluating galinpepimut-S, or GPS, in patients with acute myeloid leukemia, or AML, has reached the pre-specified 80th event,…
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
Sellas Life Sciences falls -13.1%
Sellas Life Sciences (SLS) is down -13.1%, or -$1.49 to $9.85.
Sellas Life Sciences falls -12.5%
Sellas Life Sciences (SLS) is down -12.5%, or -$1.42 to $9.92.
Sellas Life Sciences put volume heavy and directionally bearish
Bearish flow noted in Sellas Life Sciences (SLS) with 9,677 puts trading, or 3x expected. Most active are Jan-27 10 puts and Oct-26 15 calls, with total volume in those…
Sellas Life Sciences presents preclinical data on SLS009 at AACR Conference
SELLAS Life Sciences (SLS) Group announced preclinical data from studies evaluating SLS009, its highly selective cyclin-dependent kinases 9 inhibitor, in patient-derived organoid models of pancreatic ...
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the Uni...
SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon
SELLAS Life Sciences stock was a hot topic among retail traders on Monday as the company is getting closer to reporting data from its Phase 3 REGAL trial.
Moderna data bode well for Sellas into imminent readout, says Maxim
Maxim views Moderna’s (MRNA) melanoma mRNA cancer vaccine results this morning as a “win for cancer vaccines.” Sellas Life Sciences (SLS) has galinpepimut-S in a Phase 3 study for patients…
Sellas Life Sciences price target raised to $35 from $25 at Alliance Global
Alliance Global analyst James Molloy raised the firm’s price target on Sellas Life Sciences (SLS) to $35 from $25 and keeps a Buy rating on the shares. The firm says…
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnos...
SELLAS Life Sciences Group Quarterly report: Q2 2026
SELLAS Life Sciences Group has published its Q2 2026 quarterly earnings report on August 11, 2026.
SELLAS Life Sciences Group Earnings release: Q2 2026
SELLAS Life Sciences Group released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Sellas Life Sciences rises 11.0%
Sellas Life Sciences (SLS) is up 11.0%, or $1.29 to $13.04.
Sellas Life Sciences rises 10.2%
Sellas Life Sciences (SLS) is up 10.2%, or $1.20 to $12.95.
Sellas Life Sciences price target raised to $25 from $10 at Alliance Global
Alliance Global analyst James Molloy raised the firm’s price target on Sellas Life Sciences (SLS) to $25 from $10 and keeps a Buy rating on the shares as the firm…
Sellas Life Sciences falls -11.0%
Sellas Life Sciences (SLS) is down -11.0%, or -$1.63 to $13.13.
What's driving SLS stock higher today and what comes next?
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and pr...
SELLAS Life Sciences Group Transcript: AGM 2026
The meeting saw strong shareholder support for all proposals, including director elections, auditor ratification, and an expanded equity plan. Financial performance was robust, with significant growth in market cap and cash reserves, while late-stage clinical programs advanced toward key data milestones.
SELLAS Life Sciences Group Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
GPS is nearing pivotal phase III data in AML, with delayed event accrual suggesting longer survival and strong prior efficacy. SLS009 shows high response rates in venetoclax-resistant AML, with top-line phase II data expected by year-end.
SELLAS Life Sciences Group Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Late-stage oncology company advancing GPS (phase III, AML maintenance) and SLS-009 (phase II, frontline AML), both showing strong efficacy and safety signals. Key data readouts for both assets are expected by year-end, supported by a robust $110M cash position.
SELLAS Life Sciences Group Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is advancing two late-stage oncology assets, GPS and SLS009, both targeting AML with promising survival and response data. Imminent catalysts include phase III REGAL trial results for GPS and phase II data for SLS009, supported by strong biomarker strategies and financial resources.